JPMorgan raised the firm’s price target on Fresenius Medical (FMS) to EUR 41.50 from EUR 37.30 and keeps an Underweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical Care Reports Strong Earnings Growth
- Fresenius Medical Care Files 2024 Annual Report with SEC
- Fresenius Medical Care Reports Strong 2024 Financial Results and Raises 2025 Targets
- Cautious Optimism: Hold Rating for Fresenius Medical Care Amid Positive Q3 Performance and 2025 Growth Projections
- Fresenius Medical price target raised to EUR 39 from EUR 37 at Morgan Stanley